Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Noninterventional, Prospective Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Moderate to Severe Plaque Psoriasis in Daily Practice

NCT04053881 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT04053881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04053881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Noninterventional, Prospective Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Moderate to Severe Plaque Psoriasis in Daily Practice
Lead sponsor
UCB Biopharma SRL
Phase
Observational
Overall status
Completed
Start date
August 21, 2019
Completion date
December 2, 2022
Enrollment
412 (actual)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis